Organicell Regenerative Medicine, Inc. (OCEL)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Organicell Regenerative Medicine, Inc. (OCEL) trades at $2.74 with AI Score 49/100 (Grade C). Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company focused on developing biological therapeutics for degenerative diseases. Market cap: $19.97M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for OCEL: OCEL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OCEL against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
OCEL: the 1 perspectives are evenly split.
How is this calculated? →Organicell Regenerative Medicine, Inc. (OCEL) Healthcare & Pipeline Overview
Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company developing biological therapeutics, primarily Zofin, for degenerative diseases. Zofin, derived from perinatal sources, is currently in Phase I/II clinical trials for COVID-19, positioning Organicell within the regenerative medicine sector alongside competitors like AMHV and ATHJF.
What Is the Investment Thesis for OCEL?
Organicell Regenerative Medicine, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is approximately $0.02 billion, with a negative P/E ratio of -3.75, reflecting its current lack of profitability. The primary value driver is the potential success of Zofin in clinical trials, particularly its Phase I/II trial for COVID-19. Upcoming data releases from these trials will be critical catalysts. A gross margin of 81.6% indicates strong potential profitability if Zofin gains regulatory approval and achieves commercial success. However, the company's negative profit margin of -92.3% highlights the significant expenses associated with research and development. The stock's beta of 1.36 suggests higher volatility compared to the overall market. The company's success hinges on navigating the regulatory landscape and securing partnerships for manufacturing and distribution.
Based on FMP financials and quantitative analysis
OCEL Key Highlights
- Market capitalization of $19.97M reflects its small size and early stage of development.
- Negative P/E ratio of -3.75 indicates the company is currently unprofitable.
- Gross margin of 81.6% suggests strong potential profitability if products are successfully commercialized.
- Profit margin of -92.3% highlights significant R&D expenses and lack of revenue from product sales.
- Beta of 1.36 indicates higher volatility compared to the market average.
Who Are OCEL's Competitors?
OCEL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMHV American Hemp Ventures, Inc. | $0.98 | +0.00% | $16.47M | 46 |
| ATHJF Antisense Therapeutics Limited | $0.01 | -76.00% | $19.64M | 57 |
| EMMLF OKYO Pharma Limited | $0.01 | +0.00% | $22.73M | 44 |
| GRAMF TPCO Holding Corp. | $0.16 | -15.36% | $20.12M | 42 |
| KMSTF Kadimastem Ltd | $3.21 | -3.02% | $9.50M | 44 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OCEL's Key Strengths?
- Proprietary technology in perinatal-derived biologics.
- Zofin in Phase I/II clinical trials for COVID-19.
- Research collaborations with reputable institutions.
- High gross margin potential (81.6%).
What Are OCEL's Weaknesses?
- Negative profit margin (-92.3%).
- Limited revenue generation.
- Reliance on the success of Zofin.
- Small market capitalization.
What Could Drive OCEL Stock Higher?
- Data readout from Phase I/II clinical trials for Zofin in COVID-19 treatment expected in late 2026.
- Potential for securing government grants and funding for research and development.
- Progress in expanding Zofin's applications to other degenerative diseases.
- Strategic partnership discussions with larger pharmaceutical companies.
What Are the Key Risks for OCEL?
- Financial-distress signal — its Altman Z-Score of -19.14 sits in the distress zone (elevated bankruptcy risk).
- Failure of Zofin in clinical trials.
- Regulatory hurdles and delays in obtaining approvals.
- Competition from established pharmaceutical companies with greater resources.
- Financial constraints and the need for additional funding to support operations.
- Risks associated with operating in the OTC market, including limited liquidity and disclosure.
What Are the Growth Opportunities for OCEL?
- Zofin Clinical Trial Success: The successful completion of Phase I/II clinical trials for Zofin in treating COVID-19 could lead to regulatory approval and commercialization. The global market for COVID-19 therapeutics remains significant, although evolving with vaccination efforts. Positive trial results would significantly increase Organicell's valuation and attract potential partnerships. Timeline: Data readout expected in late 2026.
- Expansion of Zofin to Other Indications: Organicell can explore Zofin's potential in treating other degenerative diseases beyond COVID-19. The regenerative medicine market for conditions like osteoarthritis, Alzheimer's disease, and cardiovascular diseases is substantial. Successful preclinical and clinical studies in these areas could broaden Zofin's market reach. Timeline: Preclinical studies ongoing, with potential clinical trials starting in 2027.
- Strategic Partnerships and Licensing Agreements: Partnering with larger pharmaceutical companies for manufacturing, distribution, and commercialization of Zofin can accelerate its market penetration. Licensing agreements in specific geographic regions or for specific indications can generate revenue and reduce financial risk. Timeline: Ongoing discussions, with potential agreements in 2026-2027.
- Government Grants and Funding: Securing government grants and funding for research and development can reduce Organicell's financial burden and support its clinical programs. Government agencies and foundations are increasingly investing in regenerative medicine research. Timeline: Ongoing applications, with potential awards in 2026.
- Development of New Biologic Therapeutics: Expanding the pipeline with new biologic therapeutics targeting other degenerative diseases can diversify Organicell's product portfolio and reduce its reliance on Zofin. This requires investment in research and development and the acquisition of new technologies or intellectual property. Timeline: Research and development ongoing, with potential new product candidates in 2028.
What Opportunities Does OCEL Have?
- Expansion of Zofin to other degenerative diseases.
- Strategic partnerships for manufacturing and distribution.
- Government grants and funding for research.
- Development of new biologic therapeutics.
What Threats Does OCEL Face?
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Financial constraints and need for additional funding.
What Are OCEL's Competitive Advantages?
- Proprietary technology in deriving and manufacturing Zofin from perinatal sources.
- Intellectual property protection for Zofin and its therapeutic applications.
- Established research collaborations with the CDC and Oklahoma State University.
- First-mover advantage in developing perinatal-derived biologics for specific indications.
What Does OCEL Do?
Organicell Regenerative Medicine, Inc., founded in 2011 and headquartered in Miami, Florida, is a clinical-stage biopharmaceutical company dedicated to the development of biological therapeutics for treating degenerative diseases. Originally incorporated as Biotech Products Services and Research, Inc., the company rebranded to Organicell Regenerative Medicine, Inc. in June 2018 to better reflect its focus on regenerative medicine. The company's primary product candidate, Zofin, is an acellular, biologic therapeutic derived from perinatal sources. Zofin is manufactured to retain naturally occurring microRNAs without any additives or diluents. Currently, Zofin is undergoing Phase I/II clinical trials as a potential treatment for COVID-19. Beyond its therapeutic development, Organicell also provides education, advertising, and marketing services to medical, healthcare, anti-aging, and regenerative service providers. The company has established research collaborations, including an agreement with the Centers for Disease Control and Prevention (CDC) to investigate Zofin's anti-inflammatory and anti-infective properties in influenza models and an agreement with Oklahoma State University to assess Zofin's efficacy in treating respiratory diseases caused by viruses with pandemic potential.
What Products and Services Does OCEL Offer?
- Develop biological therapeutics for degenerative diseases.
- Focus on acellular, biologic therapeutics derived from perinatal sources.
- Manufacture Zofin, a therapeutic retaining naturally occurring microRNAs.
- Conduct Phase I/II clinical trials for Zofin to treat COVID-19.
- Provide education, advertising, and marketing services to medical and healthcare providers.
- Collaborate with the CDC to study Zofin's effectiveness against influenza.
- Partner with Oklahoma State University to evaluate Zofin for respiratory diseases.
How Does OCEL Make Money?
- Develop and commercialize biological therapeutics for degenerative diseases.
- Generate revenue through potential sales of Zofin, pending regulatory approval.
- Provide education, advertising, and marketing services to healthcare providers.
- Seek research and development funding through grants and partnerships.
What Industry Does OCEL Operate In?
Organicell operates within the competitive biotechnology industry, focusing on regenerative medicine. The market for regenerative medicine is projected to experience substantial growth, driven by increasing demand for therapies addressing degenerative diseases and aging-related conditions. Companies like AMHV, ATHJF, EMMLF, GRAMF, and KMSTF also operate in this space, developing various regenerative therapies. Organicell's focus on perinatal-derived biologics differentiates it within the market. The industry is characterized by high research and development costs, stringent regulatory requirements, and a lengthy time-to-market for new therapies.
Who Are OCEL's Key Customers?
- Patients suffering from degenerative diseases, including COVID-19.
- Medical and healthcare providers seeking regenerative medicine solutions.
- Research institutions and government agencies interested in biological therapeutics.
ROE 330%Key Financial Metrics
Return on equity for Organicell Regenerative Medicine, Inc. stands at 329.9%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -6.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.70 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -26.6%, the inverse of the P/E and a quick read on earnings relative to price.
How Organicell Regenerative Medicine, Inc. Is Valued
Organicell Regenerative Medicine, Inc. carries a market capitalization of $19.97M, placing it in the micro-cap category. Relative to its peer group, OCEL's quantitative score of 49/100 is roughly in line with the peer average of 47/100.
F-Score 5/9Financial Health
Organicell Regenerative Medicine, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -19.14 places it in the distress zone, a signal of elevated financial risk.
OCEL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary technology in perinatal-derived biologics.
- Zofin in Phase I/II clinical trials for COVID-19.
- Research collaborations with reputable institutions.
- High gross margin potential (81.6%).
Bear Case
- Negative profit margin (-92.3%).
- Limited revenue generation.
- Reliance on the success of Zofin.
- Small market capitalization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
OCEL Latest News
No recent news available for OCEL.
OCEL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OCEL.
Price Targets
Wall Street price target analysis for OCEL.
OCEL MoonshotScore
What does this score mean?
The MoonshotScore rates OCEL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Harry L. Leider FACPE,
CEO
Harry L. Leider brings extensive experience in healthcare management and leadership to Organicell. His background includes serving in executive roles at various healthcare organizations, focusing on strategic planning, operational efficiency, and business development. He is a Fellow of the American College of Physician Executives (FACPE), demonstrating his commitment to professional excellence in healthcare leadership. Leider's expertise encompasses areas such as healthcare delivery, managed care, and pharmaceutical services.
Track Record: Under Harry L. Leider's leadership, Organicell has focused on advancing the clinical development of Zofin and establishing strategic partnerships. Key milestones include initiating Phase I/II clinical trials for COVID-19 and securing research agreements with the CDC and Oklahoma State University. Leider has also overseen the company's efforts to expand its intellectual property portfolio and explore new therapeutic applications for its biologic therapeutics.
OCEL OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Organicell Regenerative Medicine, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, lower trading volume, and may be subject to greater regulatory scrutiny. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies do not have to adhere to strict listing standards, potentially increasing investment risk.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Limited regulatory oversight compared to exchange-listed companies.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Check for any legal or regulatory issues involving the company.
- Review the company's investor relations materials and press releases.
- Consult with a financial advisor before investing.
- Phase I/II clinical trials for Zofin.
- Research agreements with the CDC and Oklahoma State University.
- CEO with experience in healthcare management.
- Focus on developing biological therapeutics for degenerative diseases.
What Investors Ask About Organicell Regenerative Medicine, Inc. (OCEL) — Healthcare
What does Organicell Regenerative Medicine, Inc. do?
Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company focused on developing biological therapeutics for the treatment of degenerative diseases. Its lead product candidate, Zofin, is an acellular, biologic therapeutic derived from perinatal sources and is currently in Phase I/II clinical trials for COVID-19. The company also provides education, advertising, and marketing services to medical and healthcare providers, and collaborates with research institutions to explore new therapeutic applications for its products.
What do analysts say about OCEL stock?
As of March 17, 2026, there is no readily available analyst consensus on OCEL stock due to its OTC listing and early stage of development. Key valuation metrics such as P/E ratio (-3.75) and profit margin (-92.3%) reflect the company's current lack of profitability. The primary growth consideration is the successful development and commercialization of Zofin, which is subject to clinical trial outcomes and regulatory approvals. Investors should conduct their own due diligence and consider the risks associated with investing in a small, OTC-listed biotechnology company.
What are the main risks for OCEL?
The main risks for Organicell Regenerative Medicine, Inc. include the potential failure of Zofin in clinical trials, regulatory hurdles and delays in obtaining approvals, competition from established pharmaceutical companies with greater resources, financial constraints and the need for additional funding, and risks associated with operating in the OTC market, including limited liquidity and disclosure. The company's reliance on the success of Zofin also poses a significant risk, as any setbacks in its development could negatively impact the company's valuation and prospects.
What are the key factors to evaluate for OCEL?
Organicell Regenerative Medicine, Inc. (OCEL) holds an AI score of 49/100 (low). Not financial advice.
How frequently does OCEL data refresh on this page?
OCEL prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven OCEL's recent stock price performance?
Organicell Regenerative Medicine, Inc. (OCEL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary technology in perinatal-derived biologics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OCEL overvalued or undervalued right now?
Valuing Organicell Regenerative Medicine, Inc. (OCEL) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying OCEL?
Before investing in Organicell Regenerative Medicine, Inc. (OCEL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.
- AI analysis pending for OCEL.